β-Glucocerebrosidase activity in GBA -linked Parkinson disease
Authors:
- Young Eun HuhYHYoung Eun Huh
- Ming Sum Ruby ChiangMCMing Sum Ruby Chiang
- Joseph J. LocascioJLJoseph J. Locascio
- Zhixiang LiaoZLZhixiang Liao
- Ganqiang LiuGLGanqiang Liu
- Karbi ChoudhuryKCKarbi Choudhury
- Yuliya I. KurasYKYuliya I. Kuras
- Idil TuncaliITIdil Tuncali
- Aleksandar VidenovicAVAleksandar Videnovic
- Ann L. HuntAHAnn L. Hunt
- Michael A. SchwarzschildMSMichael A. Schwarzschild
- Albert Y. HungAHAlbert Y. Hung
- 15 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 95 (6) , e685-e696
Abstract
Objective To test the relationship between clinically relevant types of GBA mutations (none, risk variants, mild mutations, severe mutations) and β-glucocerebrosidase activity in patients with Parkinson disease (PD) in cross-sectional and longitudinal case-control studies. Methods A total of 481 participants from the Harvard Biomarkers Study (HBS) and the NIH Parkinson9s Disease Biomarkers Program (PDBP) were analyzed, including 47 patients with PD carrying GBA variants (GBA-PD), 247 without a GBA variant (idiopathic PD), and 187 healthy controls. Longitudinal analysis comprised 195 participants with 548 longitudinal measurements over a median follow-up period of 2.0 years (interquartile range, 1–2 years). Results β-Glucocerebrosidase activity was low in blood of patients with GBA-PD compared to healthy controls and patients with idiopathic PD, respectively, in HBS (p < 0.001) and PDBP (p < 0.05) in multivariate analyses adjusting for age, sex, blood storage time, and batch. Enzyme activity in patients with idiopathic PD was unchanged. Innovative enzymatic quantitative trait locus (xQTL) analysis revealed a negative linear association between residual β-glucocerebrosidase activity and mutation type with p < 0.0001. For each increment in the severity of mutation type, a reduction of mean β-glucocerebrosidase activity by 0.85 μmol/L/h (95% confidence interval, −1.17, −0.54) was predicted. In a first longitudinal analysis, increasing mutation severity types were prospectively associated with steeper declines in β-glucocerebrosidase activity during a median 2 years of follow-up (p = 0.02). Conclusions Residual activity of the β-glucocerebrosidase enzyme measured in blood inversely correlates with clinical severity types of GBA mutations in PD. β-Glucocerebrosidase activity is a quantitative endophenotype that can be monitored noninvasively and targeted therapeutically.Keywords
This publication has 39 references indexed in Scilit:
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2Annals of Neurology, 2011
- Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker StudyMovement Disorders, 2011
- α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher DiseasesJournal of Biological Chemistry, 2011
- CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathyProceedings of the National Academy of Sciences, 2011
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseNew England Journal of Medicine, 2009
- GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synucleinProceedings of the National Academy of Sciences, 2008
- The Need for Appropriate Genotyping Strategies for Glucocerebrosidase Mutations in Cohorts With Parkinson DiseaseArchives of Neurology, 2008
- Molecular markers of early Parkinson's disease based on gene expression in bloodProceedings of the National Academy of Sciences, 2007